Cancer Immunotherapy And Biomarkers
32 researchers across 5 institutions
Researchers investigate how the immune system can be harnessed to fight cancer. This work involves identifying and characterizing immune cells and molecules that play a role in tumor development and destruction. Studies explore strategies to enhance anti-cancer immune responses, such as developing novel immunotherapies and understanding mechanisms of immune evasion by cancer cells. A significant focus is placed on discovering and validating biomarkers that can predict patient response to treatment, aid in early cancer detection, and monitor disease progression. This includes analyzing genetic, molecular, and cellular profiles of tumors and the tumor microenvironment.
This research holds particular relevance for Arkansas by addressing cancer burdens within the state. By uncovering effective immunotherapies and reliable biomarkers, this work aims to improve treatment outcomes for cancer patients across Arkansas, potentially reducing healthcare costs and enhancing quality of life. Understanding the genetic and environmental factors that influence cancer and immune responses can also inform public health initiatives and cancer prevention strategies tailored to the state's diverse population.
This area of study draws on expertise from molecular biology, pharmacology, and disease modeling. Investigations into immune cell function, inflammation, and cancer cell biology are integral to advancing cancer immunotherapy and biomarker discovery. Engagement spans multiple institutions across Arkansas, fostering a collaborative environment for tackling complex cancer challenges.
Top Researchers
| Name | Institution | h-index | Citations | Career Stage | Badges |
|---|---|---|---|---|---|
| Martin J. Cannon | UAMS | 44 | 5,926 | Grant PI High Impact | |
| Xinyu Li | University of Arkansas | 43 | 5,893 | High Impact | |
| Thomas Kieber‐Emmons | UAMS | 42 | 5,583 | ||
| Andrew J. Pierce | Ouachita Baptist University | 34 | 7,626 | High Impact | |
| Yong‐Chen Lu | UAMS | 28 | 12,542 | High Impact | |
| Yan Cheng | UAMS | 26 | 2,229 | ||
| Behjatolah Monzavi‐Karbassi | UAMS | 24 | 1,617 | Grant PI High Impact | |
| César Sánchez | UAMS | 20 | 2,481 | High Impact | |
| Fariba Jousheghany | UAMS | 14 | 701 | ||
| Andrew Johns | University of Central Arkansas | 12 | 525 | ||
| Takeo Shibata | UAMS | 12 | 493 | ||
| Duah Alkam | UAMS | 11 | 493 | ||
| Teresa Evans | UAMS | 10 | 466 | ||
| Dong Wang | NCTR | 9 | 252 | ||
| Jessica L. Kelliher | UAMS | 8 | 721 | ||
| Shelby N. Bess | University of Arkansas | 5 | 66 | ||
| Bahaa Mustafa | UAMS | 4 | 100 | ||
| Vivek Yadala | UAMS | 4 | 105 | ||
| Khandoker Usran Ferdous | UAMS | 4 | 66 | ||
| Amir Mahari | University of Arkansas | 4 | 243 |
Related Research Areas
Strategic Outlook
Global signals from OpenAlex for this research area: where the field is growing, how concentrated leadership is, and where Arkansas sits relative to the world's top-100 institutions. Descriptive only — surfaced as input to the conversation about where to place bets, not a recommendation. Signal confidence: LOW
Top US institutions in this area
- 1 Harvard University 6,699
- 2 National Institutes of Health 6,452
- 3 National Cancer Institute 5,219
- 4 The University of Texas MD Anderson Cancer Center 3,937
- 5 University of Pennsylvania 3,489
Cross-Institution Connections
Researchers at different institutions with overlapping expertise in Cancer Immunotherapy And Biomarkers.